TABLE III.

Significant subset analyses from selected trials, which may guide patient-adapted treatment

Reference (study name)	Agent	Analysis subset	Pts (n)	Hazard ratio
				pfs	os
Switch maintenance
Ciuleanu et al., 200918 (jmen)	Pemetrexed	Squamous	182	1.03	1.07
		Non-squamous	481	0.47	0.70
		Non-squamous, cr/pr	322	nr	0.81
		Non-squamous, sd	337	nr	0.61
Fidias et al., 200917	Docetaxel	cr/pr		nr	nr
		sd		nr	nr
Cappuzzo et al., 201025 (saturn)	Erlotinib	Squamous		0.76	0.86
		Non-squamous		0.60	0.77
		EGFR mutation–positive	49	0.23	0.83
		EGFR mutation–negative	388	0.78	0.77
		cr/pr	394	0.74	0.94
		sd	487	0.68	0.72
Kabbinavar et al., 201035 (atlas)	Erlotinib–bevacizumab	EGFR mutation–positive	52	0.44	nr
		EGFR mutation–negative	295	0.85	nr
Perol et al., 201026 (ifct-gfpc 0502)	Erlotinib	cr/pr	160	0.80	nr
		sd	145	0.85	nr
Zhang et al., 201129 (inform)	Gefitinib	EGFR mutation–positive	30	0.17	nr
		EGFR mutation–negative	49	0.87	nr
Continuation maintenance
Perol et al., 201026 (ifct-gfpc 0502)	Gemcitabine	cr/pr	155	0.44	nr
		sd	146	0.68	nr
Paz–Ares et al., 201122 (paramount)	Pemetrexed	All non-squamous:
		cr/pr	242	0.48	nr
		sd	280	0.74	nr

Pts = patients; pfs = progression-free survival; os = overall survival; cr/pr = complete/partial response; nr = not reported; sd = stable disease.